rs111033394
Variant summary
Our verdict is Benign. Variant got -16 ACMG points: 0P and 16B. BP4_StrongBP6_Very_StrongBS2
The NM_206933.4(USH2A):āc.7130A>Gā(p.Asn2377Ser) variant causes a missense change. The variant allele was found at a frequency of 0.00423 in 1,610,458 control chromosomes in the GnomAD database, including 28 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Likely benign (ā ā ). Synonymous variant affecting the same amino acid position (i.e. N2377N) has been classified as Likely benign.
Frequency
Consequence
NM_206933.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -16 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
USH2A | NM_206933.4 | c.7130A>G | p.Asn2377Ser | missense_variant | 38/72 | ENST00000307340.8 | NP_996816.3 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
USH2A | ENST00000307340.8 | c.7130A>G | p.Asn2377Ser | missense_variant | 38/72 | 1 | NM_206933.4 | ENSP00000305941 | P1 | |
USH2A | ENST00000674083.1 | c.7130A>G | p.Asn2377Ser | missense_variant | 38/73 | ENSP00000501296 |
Frequencies
GnomAD3 genomes AF: 0.00382 AC: 580AN: 152012Hom.: 4 Cov.: 32
GnomAD3 exomes AF: 0.00392 AC: 981AN: 250098Hom.: 8 AF XY: 0.00382 AC XY: 517AN XY: 135184
GnomAD4 exome AF: 0.00427 AC: 6225AN: 1458328Hom.: 24 Cov.: 31 AF XY: 0.00410 AC XY: 2973AN XY: 725236
GnomAD4 genome AF: 0.00381 AC: 580AN: 152130Hom.: 4 Cov.: 32 AF XY: 0.00398 AC XY: 296AN XY: 74368
ClinVar
Submissions by phenotype
not provided Benign:5
Benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 31, 2024 | - - |
Benign, criteria provided, single submitter | clinical testing | ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories | Aug 20, 2021 | - - |
Likely benign, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Jan 01, 2024 | USH2A: BP4, BS2 - |
Benign, criteria provided, single submitter | clinical testing | GeneDx | Jun 12, 2018 | This variant is associated with the following publications: (PMID: 25910913, 26927203, 22004887) - |
Likely benign, criteria provided, single submitter | not provided | Breakthrough Genomics, Breakthrough Genomics | - | - - |
not specified Benign:3
Benign, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Mar 05, 2022 | Variant summary: USH2A c.7130A>G (p.Asn2377Ser) results in a conservative amino acid change in the encoded protein sequence. Four of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 0.0039 in 250098 control chromosomes in the gnomAD database, including 8 homozygotes. This frequency is not significantly higher than estimated for a pathogenic variant in USH2A causing Usher Syndrome (0.0039 vs 0.011), allowing no conclusion about variant significance. Although reported in the literature, to our knowledge, no penetrant association of c.7130A>G in individuals affected with Usher Syndrome and no experimental evidence demonstrating its impact on protein function have been reported. Six clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. All laboratories classified the variant as benign/likely benign. Based on the evidence outlined above, the variant was classified as benign. - |
Benign, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | Dec 19, 2014 | - - |
Benign, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Apr 27, 2012 | Asn2377Ser in exon 38 of USH2A: This variant is not expected to have clinical si gnificance because it has been identified in 0.5% (35/7016) of European American chromosomes and 0.1% (7/3738) of African American chromosomes in a broad popula tion by the NHLBI Exome sequencing project (http://evs.gs.washington.edu/EVS/; d bSNP rs111033394). - |
Usher syndrome type 2A Benign:2
Likely benign, no assertion criteria provided | clinical testing | Natera, Inc. | Jun 12, 2020 | - - |
Likely benign, criteria provided, single submitter | clinical testing | Genome-Nilou Lab | Nov 04, 2023 | - - |
Usher syndrome type 2A;C3151138:Retinitis pigmentosa 39 Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Counsyl | Dec 28, 2016 | - - |
Retinitis pigmentosa 39 Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Genome-Nilou Lab | Nov 04, 2023 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at